Toll Free: 1-888-928-9744

Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017

Published: Aug 8, 2017 | Pages: 45 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017, provides an overview of the Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline landscape.

Shigella Infections (Shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps and fever. Predisposing factors include eating contaminated food, age, international travelers and homosexual men. Treatment includes antibiotics. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 2 and 1 molecules, respectively.

Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Bacillary Dysentery (Shigellosis) - Overview Bacillary Dysentery (Shigellosis) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Bacillary Dysentery (Shigellosis) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Bacillary Dysentery (Shigellosis) - Companies Involved in Therapeutics Development Akthelia Pharmaceuticals Ltd GlaxoSmithKline Plc Immuron Ltd Microbiotix Inc Protein Potential LLC Bacillary Dysentery (Shigellosis) - Drug Profiles (shigella + typhoid) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress AKT-10081 - Drug Profile Product Description Mechanism Of Action R&D Progress GVXNSD-133 - Drug Profile Product Description Mechanism Of Action R&D Progress KKL-35 - Drug Profile Product Description Mechanism Of Action R&D Progress SC-599 - Drug Profile Product Description Mechanism Of Action R&D Progress SE-1 - Drug Profile Product Description Mechanism Of Action R&D Progress SF2a-TT15 - Drug Profile Product Description Mechanism Of Action R&D Progress shigella [serotype 2a] (whole cell) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress shigella [strain 53G] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress shigella vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress shigella vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress shigella vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Shigetec - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress WRSs-2 - Drug Profile Product Description Mechanism Of Action R&D Progress WRSs-3 - Drug Profile Product Description Mechanism Of Action R&D Progress Bacillary Dysentery (Shigellosis) - Dormant Projects Bacillary Dysentery (Shigellosis) - Discontinued Products Bacillary Dysentery (Shigellosis) - Product Development Milestones Featured News & Press Releases Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Bacillary Dysentery (Shigellosis) - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2017 Bacillary Dysentery (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H2 2017 Bacillary Dysentery (Shigellosis) - Pipeline by Immuron Ltd, H2 2017 Bacillary Dysentery (Shigellosis) - Pipeline by Microbiotix Inc, H2 2017 Bacillary Dysentery (Shigellosis) - Pipeline by Protein Potential LLC, H2 2017 Bacillary Dysentery (Shigellosis) - Dormant Projects, H2 2017 Bacillary Dysentery (Shigellosis) - Discontinued Products, H2 2017


List of Figures
Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...

Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growt

Read More...

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify